- 48
- 32 389
Guardant Health
United States
เข้าร่วมเมื่อ 26 มิ.ย. 2014
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext®, and Guardant360 Response™ tests for advanced stage cancer patients, and Guardant Reveal® for early-stage, post-surgery cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield™ test, aims to address the needs of individuals eligible for cancer screening.
How Guardant Health Conquers Cancer with Data
Discover how Guardant Health is advancing the role of blood-based cancer screening tests and liquid biopsies in early cancer detection and precision oncology.
Explore more of the insightful interview featured on Reuters: www.reuters.com/plus/acumen/g...
Explore more of the insightful interview featured on Reuters: www.reuters.com/plus/acumen/g...
มุมมอง: 1 658
วีดีโอ
Dr. Shepherd's Approach to Lung Cancer Treatment
มุมมอง 2302 หลายเดือนก่อน
To learn more: For patients: www.guardantcomplete.com/pati... For healthcare professionals: www.guardantcomplete.com/prod... Indication Statement(s): Guardant360® is a laboratory developed test that identifies potential tumor-related genomic alterations through analysis of cfDNA that is circulating in blood. Tumor or biopsy sample is not needed to perform this test. Guardant360 can be used in p...
Dennis' Shield™ Story: Screening for Colorectal Cancer
มุมมอง 1192 หลายเดือนก่อน
Dennis shares his experience getting screened with the Shield blood test. Important Product Information Intended Use The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is indicated for colorectal cancer screening in individuals at average ri...
Epigenomics in Precision Oncology
มุมมอง 8703 หลายเดือนก่อน
Discover how epigenomics is transforming precision oncology, uncovering unique molecular signatures that personalize cancer treatment strategies. Learn more about Guardant Infinity™, the first commercially available platform that unlocks both epigenomics and genomics to transform precision oncology at www.guardantcomplete.com/biopharma/multiomic-solution#infinity Copyright © Guardant Health 2024
Enabling In-Country Liquid Biopsy Testing Around the Globe with Guardant360®
มุมมอง 1584 หลายเดือนก่อน
Access to a trusted liquid biopsy test can significantly vary by country and region. Global access to our Guardant Health liquid biopsy tests is one of our top priorities. That’s why we’re partnering with labs and world-renowned cancer centers around the globe to ensure that we can bring liquid biopsy to new markets while maintaining our high quality and performance standards. Hear more from ou...
Kirk’s Guardant360® Story with Non-Small Cell Lung Cancer
มุมมอง 4625 หลายเดือนก่อน
Kirk and his wife, Jayne, share their story of how Kirk was diagnosed with Stage IV non-small cell lung cancer, worked with his doctor to use Guardant360 to help guide his treatment plan, and have survived (and thrived) for 10 years without having been on chemotherapy. To learn more: For patients: www.guardantcomplete.com/patients/cancer-blood-tests For healthcare professionals: www.guardantcom...
Q&A with Chief Medical Officer Craig Eagle | 500 Publications
มุมมอง 2295 หลายเดือนก่อน
Guardant Health Chief Medical Officer Dr. Craig Eagle to discusses the achievement of 500 peer-reviewed publications. Copyright © Guardant Health 2024
Webinar: Exploring Lung Cancer Care in 2024 and Beyond
มุมมอง 2306 หลายเดือนก่อน
In partnership with the Lung Cancer Policy Network, listen in as Guardant Health Senior Vice President of Global Public Affairs Jenn Higgins discusses the stigmas surrounding lung cancer with Eleanor Wheeler, Director of Oncology at The Health Policy Network and lung cancer survivor Shirley Munoz.
Jami's Shield™ Story: Conquering Cancer
มุมมอง 5017 หลายเดือนก่อน
Jami details her journey with cancer and how she screens for colorectal cancer with Shield™. Important Product Information: Intended Use: The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is indicated for colorectal cancer screening in indi...
Public Service Announcement: Don't Wait to be Screened for Colorectal Cancer
มุมมอง 853ปีที่แล้ว
With more than 150,000 lives lost to colorectal cancer (CRC) each year - and it is expected to be the #1 cancer killer of people under 50 by the year 2030 - spreading the word about the value of screening is more critical than ever. In honor of Colorectal Cancer Awareness Month in March, Guardant Health collaborated with patient advocacy group Fight CRC on the development and production of a pu...
Qué es Guardant Reveal® y ¿Cómo puede ayudar a monitorear mi tratamiento contra el cáncer
มุมมอง 194ปีที่แล้ว
Guardant Reveal es la primera prueba sin tejido para detectar enfermedad mínima; se trata de un análisis de sangre para pacientes con cáncer en estadios iniciales: puede realizarse en múltiples momentos, tanto después de la operación como durante el tratamiento. Estas pruebas ayudan a monitorear su respuesta al tratamiento y a evaluar el riesgo del cáncer colorrectal en estadios iniciales despu...
You've Taken Your Guardant360 Response™ Test - What's Next?
มุมมอง 531ปีที่แล้ว
2 weeks after taking Guardant360 Response your doctor will receive a report of your results. Watch to learn what your report can look like and what happens next.
Ya usted se hizo un análisis Guardant Reveal®. ¿Qué pasa ahora?
มุมมอง 70ปีที่แล้ว
Ahora que usted se hizo la prueba Guardant Reveal, su médico podrá esperarse los resultados en un plazo de 2-3 semanas. Vea en el video un informe de ejemplo y entérese de lo que pasará después.
¿Qué es la enfermedad residual mínima y cómo se usa para orientar el tratamiento?
มุมมอง 167ปีที่แล้ว
La enfermedad residual mínima (ERM) es una pequeña cantidad de cáncer que queda en el cuerpo después del tratamiento. Es importante detectar la ERM en el cuerpo durante y/o después del tratamiento, para monitorear la respuesta a dicho tratamiento. Obtenga más información sobre Guardant Reveal™, la primera prueba sin tejido para detectar enfermedad residual mínima (ERM) después de la cirugía del...
Ya se hizo el análisis Guardant360 Response™. ¿Qué pasa ahora?
มุมมอง 52ปีที่แล้ว
Ya se hizo el análisis Guardant360 Response™. ¿Qué pasa ahora?
¿Qué es Guardant360 Response™? ¿Cómo funciona el análisis de monitoreo del tratamiento?
มุมมอง 81ปีที่แล้ว
¿Qué es Guardant360 Response™? ¿Cómo funciona el análisis de monitoreo del tratamiento?
El papel de Guardant360 Response™: ¿Está funcionando mi tratamiento contra el cáncer?
มุมมอง 51ปีที่แล้ว
El papel de Guardant360 Response™: ¿Está funcionando mi tratamiento contra el cáncer?
¿Qué es Guardant360 TissueNext®? Y cómo puede informar el tratamiento del cáncer?
มุมมอง 89ปีที่แล้ว
¿Qué es Guardant360 TissueNext®? Y cómo puede informar el tratamiento del cáncer?
El proceso de facturación de Guardant y el formulario de explicación de beneficios
มุมมอง 36ปีที่แล้ว
El proceso de facturación de Guardant y el formulario de explicación de beneficios
Reciba el servicio de flebotomía móvil sin costo de Guardant Health
มุมมอง 105ปีที่แล้ว
Reciba el servicio de flebotomía móvil sin costo de Guardant Health
Programa Guardant Access: ¿Cómo pago los análisis Guardant Health?
มุมมอง 51ปีที่แล้ว
Programa Guardant Access: ¿Cómo pago los análisis Guardant Health?
Qué esperar después de su prueba Guardant360® CDx CGP
มุมมอง 60ปีที่แล้ว
Qué esperar después de su prueba Guardant360® CDx CGP
¿Qué es el Perfil Genómico Integral? Cómo ayuda al tratamiento del cáncer
มุมมอง 112ปีที่แล้ว
¿Qué es el Perfil Genómico Integral? Cómo ayuda al tratamiento del cáncer
What is Minimal Residual Disease & How is It Used to Inform Treatment?
มุมมอง 532ปีที่แล้ว
What is Minimal Residual Disease & How is It Used to Inform Treatment?
What is Guardant Reveal™ & How Can It Help Monitor My Cancer Treatment?
มุมมอง 1.3Kปีที่แล้ว
What is Guardant Reveal™ & How Can It Help Monitor My Cancer Treatment?
You've Taken Your Guardant Reveal™ Test - What's Next?
มุมมอง 576ปีที่แล้ว
You've Taken Your Guardant Reveal™ Test - What's Next?
Understand Guardant360 Response™: Is My Cancer Treatment Working?
มุมมอง 379ปีที่แล้ว
Understand Guardant360 Response™: Is My Cancer Treatment Working?
What is Guardant360 Response™ and How Does Treatment Monitor Testing Work?
มุมมอง 912ปีที่แล้ว
What is Guardant360 Response™ and How Does Treatment Monitor Testing Work?
Nolan Mall
Greenfelder Viaduct
Thank you for sharing!
Does medicare pay for these services?
Sin chao ba Khe không ❤❤❤❤❤
doesn't sound promising
🌷 *Promosm*
ρɾσɱσʂɱ 😝
Tous merci au Dr Aba de m'avoir guéri de cette maladie cancéreuse mortelle .......
All thanks to Dr Aba for curing my mother breast cancer am forever grateful sir
Yay Patty! Love this!